Moderna CEO: Skin Cancer Trial Results Expected by Year-End

Moderna's first-quarter sales exceeded expectations. The vaccine maker, which faced resistance from the Trump administration, has found new growth areas outside the US. The company's CEO, Stephane Bancel, stated in an interview with Bloomberg that they expect to release skin cancer trial results within this year. Moderna pleased investors by surpassing sales forecasts in the first quarter. The company recorded strong growth, particularly in markets outside the US, demonstrating its ability to strengthen its global presence despite the Trump administration's anti-vaccine stance. CEO Bancel gave positive signals regarding the progress of the skin cancer vaccine trials. The trial results are expected by the end of the year. This is seen as part of Moderna's strategy to develop new products beyond its COVID-19 vaccine. The company is also continuing its work on flu vaccines and other respiratory diseases. Moderna aims to diversify its portfolio by applying mRNA technology to different areas. This is not investment advice.